Analyst Reco. TG Therapeutics, Inc.

Equities

TGTX

US88322Q1085

Market Closed - Nasdaq Other stock markets 01:30:00 02/05/2024 am IST			5-day change	1st Jan Change
15.88 ^USD	+16.25%		+13.59%	-7.03%

01/05	Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts	MT
01/05	Transcript : TG Therapeutics, Inc., Q1 2024 Earnings Call, May 01, 2024

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

TG Therapeutics Wins Veterans Affairs Contract for Multiple Sclerosis Drug Briumvi	18/04	MT
Goldman Sachs Raises Price Target on TG Therapeutics to $13 From $12, Maintains Neutral Rating	29/02	MT
B. Riley Adjusts Price Target on TG Therapeutics to $29 From $24, Maintains Buy Rating	05/02	MT
HC Wainwright Adjusts TG Therapeutics Price Target to $45 From $41, Maintains Buy Rating	11/01	MT
B. Riley Adjusts Price Target on TG Therapeutics to $24 From $32, Keeps Buy Rating	20/23/20	MT
JPMorgan Cuts TG Therapeutics Price Target to $22 From $34, Maintains Overweight Rating	07/23/07	MT
Goldman Sachs Upgrades TG Therapeutics to Neutral From Sell, Adjusts Price Target to $12 From $16	02/23/02	MT
B. Riley Lowers TG Therapeutics' PT to $32 From $42 After Lower-Than-Expected Q2 Results, Keeps Buy Rating	02/23/02	MT
HC Wainwright Adjusts TG Therapeutics' Price Target to $41 From $34, Keeps Buy Rating	01/23/01	MT
Goldman Sachs Adjusts TG Therapeutics' Price Target to $16 From $10, Keeps Sell Rating	24/23/24	MT
Ladenburg Thalmann Raises Price Target on TG Therapeutics to $37.50 From $26, Maintains Buy Rating	02/23/02	MT
B. Riley Raises TG Therapeutics' Price Target to $42 From $39 After 'Strong' Q1 Results, Keeps Buy Rating	02/23/02	MT
HC Wainwright Adjusts Price Target on TG Therapeutics to $28 From $24, Reiterates Buy Rating	14/23/14	MT
B. Riley Raises TG Therapeutics' Price Target to $39 From $23, Keeps Buy Rating	11/23/11	MT
Cantor Fitzgerald Raises Price Target on TG Therapeutics to $24 From $18, Maintains Overweight Rating	07/23/07	MT
Evercore ISI Adjusts Price Target on TG Therapeutics to $25 From $16, Maintains Outperform Rating	24/23/24	MT
Evercore ISI Adjusts Price Target on TG Therapeutics to $16 From $11, Maintains Outperform Rating	30/22/30	MT
Goldman Sachs Adjusts Price Target on TG Therapeutics to $6 From $4, Maintains Sell Rating	30/22/30	MT
B. Riley Boosts Price Target on TG Therapeutics to $23 From $17, Keeps Buy Rating	30/22/30	MT
BofA Raises Price Target on TG Therapeutics to $6 From $5, Maintains Underperform Rating	29/22/29	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. TG Therapeutics, Inc.

Equities

TGTX

US88322Q1085

Analyst Reco.

Filters